Overview

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Phase:

Phase 1

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Seladelpar